Siemens Fonds Invest GmbH Has $1.59 Million Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Siemens Fonds Invest GmbH boosted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 561.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,002 shares of the medical equipment provider's stock after acquiring an additional 12,735 shares during the quarter. Siemens Fonds Invest GmbH's holdings in Zimmer Biomet were worth $1,585,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Royal Bank of Canada boosted its stake in shares of Zimmer Biomet by 67.3% during the 4th quarter. Royal Bank of Canada now owns 347,926 shares of the medical equipment provider's stock valued at $36,751,000 after buying an additional 139,959 shares during the last quarter. Rafferty Asset Management LLC raised its position in shares of Zimmer Biomet by 9.3% during the 4th quarter. Rafferty Asset Management LLC now owns 22,580 shares of the medical equipment provider's stock valued at $2,385,000 after acquiring an additional 1,925 shares in the last quarter. Raiffeisen Bank International AG acquired a new stake in shares of Zimmer Biomet during the 4th quarter valued at approximately $1,306,000. Quantinno Capital Management LP raised its position in shares of Zimmer Biomet by 239.8% during the 4th quarter. Quantinno Capital Management LP now owns 39,736 shares of the medical equipment provider's stock valued at $4,197,000 after acquiring an additional 28,042 shares in the last quarter. Finally, Mufg Securities Americas Inc. acquired a new stake in Zimmer Biomet in the fourth quarter worth $310,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Insider Transactions at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the sale, the senior vice president now owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This trade represents a 14.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.39% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ZBH has been the topic of several analyst reports. Robert W. Baird dropped their target price on Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Canaccord Genuity Group dropped their target price on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating on the stock in a research report on Monday, May 12th. BTIG Research reissued a "buy" rating on shares of Zimmer Biomet in a report on Monday, April 14th. Wells Fargo & Company decreased their target price on Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Finally, Barclays decreased their price target on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research report on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $113.45.

Zimmer Biomet Stock Performance

Shares of ZBH stock traded down $0.56 during trading on Tuesday, reaching $95.21. The company had a trading volume of 2,330,698 shares, compared to its average volume of 1,760,828. The firm's 50 day simple moving average is $103.24 and its two-hundred day simple moving average is $105.76. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. Zimmer Biomet Holdings, Inc. has a one year low of $89.92 and a one year high of $120.13. The company has a market capitalization of $18.84 billion, a PE ratio of 21.40, a PEG ratio of 1.95 and a beta of 0.78.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The firm had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The company's revenue was up 1.1% on a year-over-year basis. During the same quarter last year, the firm posted $1.94 EPS. Sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st were issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.01%. The ex-dividend date was Monday, March 31st. Zimmer Biomet's payout ratio is presently 21.24%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.